Stayble Therapeutics recently announced that the company's phase IIb study did not meet the primary endpoint. The drug candidate STA363 did not show a statistically significant reduction in pain compared to placebo after 6 months. The company now plans to continue evaluating top-line data from the study to create a better understanding of the results. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/stayble-did-not-reach-the-primary-endpoint-in-phase-iib/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/stayble-therapeutics/r/biostock-stayble-did-not-reach-the-primary-endpoint-in-phase-iib,c3872863

(c) 2023 Cision. All rights reserved., source Press Releases - English